期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

金复康口服液对非小细胞人肺腺癌吉非替尼获得性耐药的影响 被引量：35

在线阅读 下载PDF
导出
摘要 目的:研究金复康口服液对非小细胞人肺腺癌吉非替尼获得性耐药的影响。方法:应用血清药理学的方法,选择人肺腺癌PC-9细胞及人肺腺癌获得性耐吉非替尼PC-9R细胞株,MTT法检测细胞增殖率,计算IC50、逆转耐药倍数、协同效应;west-blot法、Real-time PCR检测P-EGFR的表达。结果:金复康口服液含药血清、金复康口服液含药血清联合吉非替尼对PC-9、PC-9R细胞的增殖抑制作用呈时效及量效关系;金复康口服液含药血清逆转吉非替尼的耐药倍数为11.3倍,Q值为2.32,大于1.15,表明两药有协同作用;金复康口服液含药血清联合吉非替尼组P-EGFR及P-EGFR mRNA的表达显著低于吉非替尼组(P<0.05)。结论:金复康口服液能逆转吉非替尼的获得性耐药,其机制可能与下调P-EGFR表达有关。
作者 孙玺媛 姜梅 张伟 梁隽婷 孙建立
机构地区 齐齐哈尔医学院附属第三医院肿瘤科 上海中医药大学附属龙华医院肿瘤科
出处 《中药材》 CAS CSCD 北大核心 2014年第7期1254-1258,共5页 Journal of Chinese Medicinal Materials
基金 黑龙江省教育厅资助项目(12521623)
关键词 金复康口服液 非小细胞肺癌 EFGR-TKI 获得性耐药
分类号 R285.5 [医药卫生—中药学]
  • 相关文献

参考文献14

  • 1周彩存,费世江.有EGFR突变的非小细胞肺癌患者吉非替尼与含铂双药化疗疗效比较[J].循证医学,2011,11(1):28-30. 被引量：3
  • 2Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,36(1):947-957.
  • 3Douillard JY,Shepherd FA,Hirsh V,et al.Molecular predictors of outcome with gefitinib and docetaxel in previously treated non small cell lung cancer:date from the randomized phase III INTEST trial[J].J Clin Oncol,2010,28(5):744-752.
  • 4Cappuzzo F,Ciuleanu T,Stelmakh L,et al.Erlotinib as maintenance treatment in advanced non small cell lung cancer:a multicentre,randomised,placebo controlled phase 3study[J].Lancet Oncol,2010,11(6):521-529.
  • 5Jackman D,Pao W,Riely GJ,et al.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].J Clin Oncol,2010,28(2):357-360.
  • 6William P,Nicolas P.New driver mutations in non small cell lung cancer[J].Lancet Oncol,2011,12(2):175-180.
  • 7Han B,Zhou X,Zhang RX,et al.Mutations of the epidermal growth factor receptor gene in NSCLC patients[J].Oncol Lett,2011,2(6):1233-1237.
  • 8Cappuzzo F,Marchetti A,Skokan M,et al.Increased MET gene copy number negatively affects survival of surgically resected non small cell lung cancer patients[J].J Clin Oncol,2009,27(10):1667-1674.
  • 9王彩霞,周晓军.非小细胞肺癌EGFR-TKIs耐药机制的研究进展[J].临床肿瘤学杂志,2013,18(3):279-284. 被引量：6
  • 10Uramoto H,Iwata T,Onitsuka T,et al.Epithelial mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma[J].Anticancer Res,2010,30(7):2513-2517.

二级参考文献39

  • 1于月新,李巨.紫草素逆转绒癌细胞JAR/MTX耐药与survivin和Bcl-2表达关系研究[J].第三军医大学学报,2007,29(19):1880-1882. 被引量：10
  • 2Inukai M,Toyooka S,Ito S,et al. Presence of epidermal growthfactor receptor gene T790M mutation as a minor clone in non-small cell lung cancer [ J]. Cancer Res, 2006,66(16) :7854-7858.
  • 3Uramoto H, Shimokawa H, Hanagiri T, et al. Expression of se-lected gene for acquired drug resistance to EGFR-TKI in lung ad-enocarcinoma[ J]. Lung Cancer, 2011,73(3) :361 -365.
  • 4Oxnard GR, Janjigian YY, Arcila ME, et al. Maintained sensi-tivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lungcancer recurring after adjuvant erlotinib or gefitinib [ J ]. ClinCancer Res, 2011, 17(19):6322 -6328.
  • 5Brugger W, Thomas M. EGFR-TKI resistant non-small cell lungcancer( NSCLC) : New developments and implications for futuretreatment[ J]. Lung Cancer, 2012,77( 1) :2 - 8.
  • 6Wang M, Zhao J, Zhang LM, et al. Combined erlotinib andcetuximab overcome the acquired resistance to epidermal growthfactor receptors tyrosine kinase inhibitor in non-small-cell lungcancer[ J ]. J Cancer Res Clin Oncol,2012,138(12): 2069-2077.
  • 7Oxnard GR. Arcila ME,Chmielecki J,et al. New strategies in o-vercoming acquired resistance to epidermal growth factor receptortyrosine kinase inhibitors in lung cancer [ J]. Clin Cancer Res,2011, 17(17) :5530 -5537.
  • 8Chen G, Kronenberger P, Teugels E, et al. Targeting the epider-mal growth factor receptor in non-small cell lung cancer cells ; theeffect of combining RNA interference with tyrosine kinase inhibi-tors or cetuximab[ J]. BMC Med, 2012, 10:28.
  • 9Zhang Z,Lee JC,Lin L,et al. Activation of the AXL kinase cau-ses resistance to EGFR-targeted therapy in lung cancer [ J ]. NatGenet, 2012, 44(8) : 852 -860.
  • 10Postel-Yinay S,Ashworth A. AXL and acquired resistance to EG-FR inhibitorsf J]. Nat Genet, 2012,27 ,44(8) : 835 - 836.

共引文献32

同被引文献508

引证文献35

二级引证文献238

中药材
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部